Lenvatinib Renal Dose Modifications
For patients with severe renal impairment (CrCl <30 mL/min), reduce lenvatinib dose to 14 mg daily for differentiated thyroid cancer (DTC) and 10 mg daily for renal cell carcinoma (RCC). 1
Baseline Renal Function Adjustments
Severe Renal Impairment (CrCl 15-29 mL/min)
The FDA-approved dosing modifications based on creatinine clearance calculated by Cockcroft-Gault equation using actual body weight are:
- DTC: Reduce from 24 mg to 14 mg once daily 1
- RCC: Reduce from 18 mg (when combined with everolimus) or 20 mg (when combined with pembrolizumab) to 10 mg once daily 1
- Endometrial carcinoma: Reduce to 10 mg once daily 1
Mild to Moderate Renal Impairment
No dose adjustment required for CrCl 30-89 mL/min 1
End-Stage Renal Disease
Lenvatinib has not been studied in patients requiring dialysis. There is no recommended dose for this population 1
Treatment-Emergent Renal Toxicity Management
Proteinuria-Based Modifications
For proteinuria ≥2 g/24 hours:
- Withhold lenvatinib until proteinuria decreases to ≤2 g/24 hours
- Resume at reduced dose per Table 2 dose reduction schedule
- Permanently discontinue for nephrotic syndrome 1
The dose reduction schedule follows a stepwise approach:
- DTC: 24 mg → 20 mg → 14 mg → 10 mg
- RCC: 18 mg → 14 mg → 10 mg → 8 mg 1
Grade 3-4 Renal Failure or Impairment
- Withhold treatment until improvement to Grade 0-1 or baseline
- Resume at reduced dose or discontinue based on severity and persistence
- Monitor closely as lenvatinib concentrations may increase with declining renal function 1
Clinical Context and Monitoring Strategy
Target urine protein-to-creatinine ratio (UPCR) <3.5 g/gCre during treatment, as this threshold has been associated with preserved renal function in real-world studies 2. Proteinuria develops in approximately 71% of patients, with grade 3 proteinuria in 36%, but careful monitoring and dose adjustment can prevent significant eGFR deterioration 2.
Risk factors for severe proteinuria requiring more intensive monitoring include:
- Age >65 years (OR 8.24)
- History of diabetes mellitus (OR 7.79)
- Pre-existing hypertension (OR 4.07) 2
The mechanism involves glomerular microangiopathy with mesangiolysis and endothelial swelling 3. While proteinuria is common, clinically meaningful renal dysfunction requiring dialysis is rare with appropriate dose management 4.
Monitoring schedule:
- Baseline: Serum creatinine, CrCl calculation, urinalysis with UPCR
- During treatment: Check UPCR and renal function every 2-4 weeks initially, then monthly once stable
- Adjust frequency based on individual toxicity profile 5
Important Caveats
For hepatocellular carcinoma (HCC), there is no recommended dose for patients with severe renal impairment, as this population was not adequately studied 1. The interplay between hepatic and renal dysfunction in HCC makes dosing particularly complex.
Lenvatinib is highly protein-bound and not dialyzable, so hemodialysis will not remove the drug in cases of overdose or severe toxicity 1.
Planned drug holidays may be beneficial for managing cumulative toxicity while maintaining disease control, particularly in patients with favorable tumor biology such as lung-only metastases 4.